- Valuation
- ₹15,920 Cr

About Sai Life Sciences
Sai Life Sciences is a publicly listed company based in Hyderabad (India) founded in 1999. Complex small molecules are discovered, developed, and manufactured for pharmaceuticals. Sai Life Sciences has raised $112.18 million across 10 funding rounds from investors including Tata Capital, TPG and HBM Healthcare Investments. The company has 3,077 employees. Sai Life Sciences was last valued at $563.73 million in July 2024. Its chief executive, as recorded, is Krishna Kanumuri. Its website sailife.com draws about 39 thousand monthly visits. Its Indian entity Sai Life Sciences Limited reported revenue of βΉ2,242 Cr. Its focus areas include Biopharma Outsourcing, CRO, Drug Discovery and Medicinal Chemistry.
Company details
Sai Life Sciences was founded in 1999 in Hyderabad, India, and operates in the pharmaceutical sector. Services in drug discovery, development, and manufacturing of complex small molecules are offered, including synthetic and medicinal chemistry, pre-clinical toxicology, and DMPK studies. CMC operations cover pre-formulation, analytical development, stability studies, lyophilization, liposome processes, and formulation development.
Recognitions & Rankings of Sai Life Sciences
- Market Cap₹38,018 Cr
SAILIFE · NSE
- Share Price₹1,801.00
+0.70% today
- Revenue₹2,192 Cr
FY 2025-26 · +29.4% YoY
- EBITDA₹625 Cr
Margin 28.5%
- Net Profit₹356 Cr
FY 2025-26 · +107.4% YoY
- P/E (TTM)97.4x
P/B 13.9x
- ROE15.1%
ROCE 19.1%
- Debt / Equity0.14
Interest cover 8.9x
- Total Equity Funding$112.18M (USD)
in 10 rounds
- Latest Funding Round$1.14M (USD), Angel Round
Jul 2024
- InvestorsTata Capital
& 14 more
- Employee Count3,077
Associated legal entities of Sai Life Sciences
Sai Life Sciences is associated with 3 registered companies on The Company Check; the primary company is Sai Life Sciences Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Sai Life Sciences Limited Listed CIN L24110TG1999PLC030970 | Active | 25 Jan 1999 | Hyderabad, Telangana | ₹2,242 Cr | 2,995 | 9 | View details |
| Sai Life Pharma Private Limited CIN U24290TG2019PTC136370 | Active | 25 Oct 2019 | Hyderabad, Telangana | ₹3.0 Cr | 1 | 6 | View details |
| Sai Life Drugform Private Limited CIN U24230TG2019PTC137297 | Strike Off | 03 Dec 2019 | Hyderabad, Telangana | 2 | View details |
Apps and channels of Sai Life Sciences
its YouTube channel Sai Life Sciences has 1.48K subscribers and 30 videos.
Videos from Sai Life Sciences
The most watched videos on Sai Life Sciences's YouTube channel, Sai Life Sciences (1.48K subscribers). Click a video to play it here.
More on Sai Life Sciences.
Funding Insights of Sai Life Sciences
Sai Life Sciences has successfully raised a total of $112.18M across 10 strategic funding rounds. The most recent funding activity was a Angel Round of $1.14 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $112.18M
- Total Rounds 10
- Last Round Angel Round β $1.14M
- First Round $1.57M
(Aug 2006)
- Investors Count 15
All 10 funding rounds of Sai Life Sciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2024 | $1.14M | Angel Round | $563.73M | Fred Cohen | β |
| Jul 2022 | $99,467 | Angel Round | $394.5M | Jagdish V Dore | β |
| Jul 2021 | $106,922 | Angel Round | $β’β’β’β’β’ | Jagdish V Dore | β |
| Jul 2020 | $106,065 | Angel Round | $β’β’β’β’β’ | Jagdish V Dore | β |
| Mar 2019 | $41.65M | Series C | $β’β’β’β’β’ | TPG | |
| Jun 2018 | $4M | Series C | β | HBM Healthcare Investments | β |
| Jan 2016 | $31M | Series C | $β’β’β’β’β’ | β | |
| Apr 2008 | $20.02M | Series B | $β’β’β’β’β’ | MPM Capital | β |
| Oct 2007 | $12.5M | Series B | β | Sequoia Capital | β |
| Aug 2006 | $1.57M | Series A | $β’β’β’β’β’ | Advantium |
| Date | Valuation | Stage |
|---|---|---|
| Jul 2024 | $563.73M | β’β’β’β’β’β’β’β’ |
| Jul 2022 | $394.5M | β’β’β’β’β’β’β’β’ |
| Jul 2021 | $β’β’β’β’β’ | β’β’β’β’β’β’β’β’ |
| Jul 2020 | $β’β’β’β’β’ | β’β’β’β’β’β’β’β’ |
| Mar 2019 | $β’β’β’β’β’ | β’β’β’β’β’β’β’β’ |
| Jan 2016 | $β’β’β’β’β’ | β’β’β’β’β’β’β’β’ |
| Apr 2008 | $β’β’β’β’β’ | β’β’β’β’β’β’β’β’ |
| Aug 2006 | $β’β’β’β’β’ | β’β’β’β’β’β’β’β’ |
Full valuation and stage history of Sai Life Sciences
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $563.73M (Jul 2024). 15 investors in total: 8 institutional and 7 angel.
Investors in Sai Life Sciences
Sai Life Sciences has secured backing from 15 investors, including angel, venture fund, and institutional investors. Prominent investors backing the company include Tata Capital, TPG and HBM Healthcare Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Fund of funds focused on pre-seed and seed-stage companies | 1992 | tpg.com | Fort Worth, United States | |
Late-stage life sciences investments are managed via VC and PE. | hbmpartners.com | Zug, Switzerland | ||
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
Sequoia Capital is engaged in venture capital investments. | 1972 | sequoiacap.com | ||
Diversified non-banking financial services are provided by Tata Capital. | 2007 | tatacapital.com | Mumbai, India | |
Invests in biotech firms developing life-saving drugs and technologies. | mpmcapital.com | |||
FC Fred Cohen | Indian angel investor, active in tech startups, limited public data available. | unknown_6de7c854dfcd4dd3b | ||
JV Jagdish V Dore | unknown_d2b9e4a5429b478f9 |
Investor details for Sai Life Sciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Sai Life Sciences Limited (Sai Life Sciences)
Sai Life Sciences Limited is the primary company behind Sai Life Sciences. The boards of the 3 registered companies of Sai Life Sciences currently have 6 directors; the longest-serving is Krishnamraju Kanumuri, appointed in 2019. 31 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Krishnamraju Kanumuri DIN 00064614 | Director | 03 Dec 2019 | 6 yrs 11 mo | Sai Life Drugform Private Limited, Sai Life Pharma Private Limited, Sai Life Sciences Limited |
| Ranga Raju Kanumuri DIN 00043186 | Director | 03 Dec 2019 | 6 yrs 11 mo | Sai Life Drugform Private Limited, Sai Life Pharma Private Limited, Sai Life Sciences Limited |
| Ramesh Ganesh Iyer DIN 00220759 | Director | 21 May 2024 | 2 yrs 6 mo | Sai Life Sciences Limited |
| Suchita Sharma DIN 10656028 | Director | 10 Jun 2024 | 2 yrs 5 mo | Sai Life Sciences Limited |
| Dinesh Vinoobhai Patel DIN 11010657 | Director | 24 Mar 2025 | 1 yr 7 mo | Sai Life Sciences Limited |
| Sivaramakrishnan Chittor DIN 01092158 | Whole-time director | 28 Apr 2025 | 1 yr 6 mo | Sai Life Sciences Limited |
People of Sai Life Sciences
86 people are tracked at Sai Life Sciences (42 in leadership, 4 in board & advisors, 40 in team); the tracked headcount is 3,077.
| Name | Role | Group |
|---|---|---|
Prathima Kanumuri | Leadership | |
Krishna Kanumuri | CEO & MD | Leadership |
Venkata Ramana Sirivolu | Senior Director | Leadership |
Sonela Cavicke | Vice President, Head Of Discovery Business Development, North America | Leadership |
Abhijit Das | Deputy General Manager - Operational Excellence | Leadership |
Monish Kulkarni | Associate Vice President Human Resources | Leadership |
Siva Chittor | Chief Financial Officer | Leadership |
Nimmagadda Sri Krishna | Associate Director | Leadership |
Carol Chouest | Senior Director Of Business Development | Leadership |
Prabhu Gudelli | Senior Vice President Manufacturing | Leadership |
Kandi Vijeender | Associate Director | Leadership |
Sidhartha Das | SVP & Head, Human Resources | Leadership |
Yadu Kishore Devayajanam | Director - Human Resources | Leadership |
Hitesh Desai | Sr.director & Head-hr (manufacturing) | Leadership |
Anil Jagdhane | Deputy General Manager | Leadership |
Tuneer Ghosh | SVP & Head, CMC Business Development | Leadership |
Damodharen Muniyandi | Chief Quality Officer | Leadership |
Bharadwaj Ps | Director | Leadership |
Maneesh Pingle | SVP & Head, Discovery Business Development | Leadership |
Abhishek Sinha | Associate Director | Leadership |
66 more people are available in the full profile.
Complete people profiles for Sai Life Sciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Sai Life Sciences
Sai Life Sciences is a publicly listed company on the NSE with ticker symbol SAILIFE in India, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date18 Dec 2024
- Listed onNSE: SAILIFE · BSE: 544306
- Listed entitySAI Life Sciences Ltd.
- Exchange sectorCommercial services
- ISININE570L01029
- Share price₹1,436.00 (-1.8% on the day) · 2026-10-14
- Market capitalisation₹31,062 Cr
- Price to earnings84.8
- EPS (diluted, trailing year)₹16.93
- Volume (last session)208,147
Financials of Sai Life Sciences
Exchange-reported figures of Sai Life Sciences Limited, the listed company behind Sai Life Sciences (NSE: SAILIFE).
Financial Highlights
FY 2025-26 Β· ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 2,192 | 1,695 | 1,465 | 1,217 | 870 | 760 | 726 |
| Revenue growth | +29.4% | +15.7% | +20.4% | +40.0% | +14.4% | +4.7% | - |
| EBITDA | 625 | 408 | 287 | 169 | 126 | 167 | 168 |
| EBITDA margin | +28.5% | +24.1% | +19.6% | +13.9% | +14.5% | +22.0% | +23.1% |
| Profit before tax | 466 | 228 | 109 | 16.41 | 9.70 | 81.91 | 109 |
| Net profit | 356 | 171 | 82.78 | 10.21 | (5.08) | 61.09 | 76.34 |
| Net profit margin | +16.2% | +10.1% | +5.7% | +0.8% | -0.6% | +8.0% | +10.5% |
| EPS (βΉ) | 16.48 | 8.16 | 46.89 | 5.67 | 3.55 | 35.06 | 46.59 |
| Balance sheet | |||||||
| Total assets | 2,804 | 2,504 | 1,924 | 1,841 | 1,841 | 1,548 | 1,145 |
| Net worth | 2,484 | 2,128 | 975 | 888 | 879 | 863 | 794 |
| Total debt | 288 | 352 | 928 | 932 | 751 | 637 | 304 |
| Cash & bank | 111 | 464 | 159 | 86.34 | 130 | 76.41 | 98.25 |
| Net working capital | 670 | 960 | 680 | 681 | 685 | 595 | 390 |
| Cash flow | |||||||
| Cash from operations | 509 | 314 | 263 | 219 | 105 | (36.38) | 116 |
| Cash from investing | (395) | (536) | (191) | (99.00) | (102) | (260) | (262) |
| Cash from financing | (124) | 301 | (95.30) | (201) | 71.92 | 296 | (4.07) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 659 | 554 | 602 | 556 | 537 | 496 | 580 | 440 |
| Revenue growth (YoY) | +22.5% | +11.7% | +3.9% | +26.5% | +35.9% | +77.5% | - | - |
| Other income | 3.97 | 3.54 | 15.81 | 8.38 | 15.33 | 9.90 | 9.60 | 9.12 |
| EBITDA | 186 | 148 | 177 | 180 | 146 | 121 | 158 | 120 |
| EBITDA margin | +28.3% | +26.7% | +29.3% | +32.3% | +27.1% | +24.4% | +27.2% | +27.2% |
| Depreciation | 48.13 | 45.94 | 45.31 | 44.08 | 39.75 | 37.72 | 37.49 | 34.09 |
| Interest | 10.94 | 7.64 | 7.83 | 9.70 | 9.35 | 12.36 | 10.89 | 23.13 |
| Profit before tax | 131 | 97.97 | 139 | 134 | 112 | 80.75 | 119 | 71.65 |
| Tax | 32.96 | 24.69 | 34.99 | 33.80 | 28.20 | 20.30 | 30.53 | 17.80 |
| Net profit | 98.33 | 73.28 | 104 | 100 | 83.85 | 60.45 | 88.27 | 53.85 |
| EPS (βΉ) | 4.58 | 3.42 | 4.87 | 4.71 | 3.93 | 2.90 | 4.14 | 2.84 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 2,153 | 1,642 | 1,419 | 1,157 | 841 | 751 | 725 |
| Revenue growth | +31.1% | +15.7% | +22.6% | +37.6% | +11.9% | +3.6% | - |
| EBITDA | 593 | 392 | 288 | 167 | 125 | 164 | 170 |
| EBITDA margin | +27.6% | +23.9% | +20.3% | +14.4% | +14.9% | +21.9% | +23.4% |
| Profit before tax | 456 | 232 | 129 | 32.68 | 22.36 | 87.59 | 114 |
| Net profit | 348 | 175 | 95.22 | 24.61 | 4.38 | 65.31 | 80.13 |
| Net profit margin | +16.2% | +10.7% | +6.7% | +2.1% | +0.5% | +8.7% | +11.1% |
| EPS (βΉ) | 16.12 | 8.32 | 53.92 | 13.76 | 8.93 | 36.65 | 48.92 |
| Balance sheet | |||||||
| Total assets | 2,763 | 2,478 | 1,899 | 1,802 | 1,790 | 1,545 | 1,137 |
| Net worth | 2,508 | 2,167 | 1,011 | 913 | 891 | 868 | 794 |
| Total debt | 223 | 287 | 868 | 869 | 751 | 637 | 304 |
| Cash & bank | 108 | 458 | 152 | 80.02 | 124 | 70.10 | 92.97 |
| Net working capital | 641 | 947 | 697 | 684 | 690 | 584 | 401 |
| Cash flow | |||||||
| Cash from operations | 495 | 330 | 251 | 221 | 88.38 | (25.94) | 109 |
| Cash from investing | (393) | (565) | (190) | (111) | (94.63) | (279) | (259) |
| Cash from financing | (109) | 314 | (84.63) | (190) | 80.95 | 304 | (1.40) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 647 | 547 | 594 | 549 | 527 | 483 | 567 | 429 |
| Revenue growth (YoY) | +22.9% | +13.2% | +4.8% | +28.1% | +37.9% | +82.6% | - | - |
| Other income | 3.84 | 3.54 | 16.04 | 8.45 | 14.93 | 10.01 | 9.82 | 9.45 |
| Total expenses | 469 | 407 | 426 | 378 | 387 | 370 | 413 | 317 |
| EBITDA | 178 | 140 | 168 | 171 | 140 | 113 | 154 | 111 |
| EBITDA margin | +27.5% | +25.6% | +28.3% | +31.1% | +26.6% | +23.4% | +27.1% | +25.9% |
| Depreciation | 44.40 | 42.13 | 41.16 | 40.60 | 36.21 | 34.33 | 34.10 | 31.07 |
| Interest | 9.33 | 5.98 | 6.16 | 8.06 | 7.70 | 10.70 | 9.16 | 21.66 |
| Profit before tax | 128 | 95.33 | 137 | 130 | 111 | 77.98 | 120 | 67.91 |
| Tax | 32.30 | 23.99 | 34.32 | 32.84 | 27.92 | 19.62 | 30.53 | 16.85 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 659 | 554 | 602 | 556 | 537 | 496 | 580 | 440 |
| Revenue growth (YoY) | +22.5% | +11.7% | +3.9% | +26.5% | +35.9% | +77.5% | - | - |
| Other income | 3.97 | 3.54 | 15.81 | 8.38 | 15.33 | 9.90 | 9.60 | 9.12 |
| EBITDA | 186 | 148 | 177 | 180 | 146 | 121 | 158 | 120 |
| EBITDA margin | +28.3% | +26.7% | +29.3% | +32.3% | +27.1% | +24.4% | +27.2% | +27.2% |
| Depreciation | 48.13 | 45.94 | 45.31 | 44.08 | 39.75 | 37.72 | 37.49 | 34.09 |
| Interest | 10.94 | 7.64 | 7.83 | 9.70 | 9.35 | 12.36 | 10.89 | 23.13 |
| Profit before tax | 131 | 97.97 | 139 | 134 | 112 | 80.75 | 119 | 71.65 |
| Tax | 32.96 | 24.69 | 34.99 | 33.80 | 28.20 | 20.30 | 30.53 | 17.80 |
| Net profit | 98.33 | 73.28 | 104 | 100 | 83.85 | 60.45 | 88.27 | 53.85 |
| EPS (βΉ) | 4.58 | 3.42 | 4.87 | 4.71 | 3.93 | 2.90 | 4.14 | 2.84 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 2,192 | 1,695 | 1,465 | 1,217 | 870 | 760 | 726 |
| Revenue growth | +29.4% | +15.7% | +20.4% | +40.0% | +14.4% | +4.7% | - |
| Other income | 49.13 | 36.78 | 29.09 | 27.97 | 28.15 | 27.29 | 17.84 |
| Total expenses | 1,568 | 1,287 | 1,178 | 1,048 | 743 | 593 | 558 |
| Employee cost | 683 | 549 | 495 | 417 | 301 | 232 | 214 |
| EBITDA | 625 | 408 | 287 | 169 | 126 | 167 | 168 |
| EBITDA margin | +28.5% | +24.1% | +19.6% | +13.9% | +14.5% | +22.0% | +23.1% |
| Depreciation | 167 | 139 | 119 | 99.43 | 90.16 | 79.57 | 54.70 |
| Interest | 40.88 | 78.34 | 87.56 | 81.02 | 54.48 | 33.14 | 21.70 |
| Profit before tax | 466 | 228 | 109 | 16.41 | 9.70 | 81.91 | 109 |
| Tax | 117 | 57.57 | 26.43 | 6.42 | 3.47 | 20.82 | 32.76 |
| Net profit | 356 | 171 | 82.78 | 10.21 | (5.08) | 61.09 | 76.34 |
| Net profit margin | +16.2% | +10.1% | +5.7% | +0.8% | -0.6% | +8.0% | +10.5% |
| EPS (βΉ) | 16.48 | 8.16 | 46.89 | 5.67 | 3.55 | 35.06 | 46.59 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 21.18 | 20.84 | 18.05 | 18.01 | 17.94 | 17.82 | 16.38 |
| Reserves & surplus | 2,463 | 2,107 | 957 | 870 | 861 | 845 | 777 |
| Shareholders' funds (net worth) | 2,484 | 2,128 | 975 | 888 | 879 | 863 | 794 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 95.13 | 129 | 710 | 699 | 718 | 603 | 291 |
| Unsecured loans | 193 | 224 | 218 | 233 | 33.80 | 33.98 | 12.42 |
| Total debt | 288 | 352 | 928 | 932 | 751 | 637 | 304 |
| Total liabilities | 2,804 | 2,504 | 1,924 | 1,841 | 1,841 | 1,548 | 1,145 |
| Assets | |||||||
| Gross block | 2,607 | 2,116 | 1,679 | 1,418 | 937 | 859 | 810 |
| Net block | 1,815 | 1,488 | 1,180 | 1,037 | 751 | 701 | 641 |
| Capital work in progress | 270 | 124 | 107 | 151 | 410 | 246 | 90.96 |
| Investments | 50.50 | 1.94 | 1.87 | 1.87 | 0.02 | 0.02 | 0.02 |
| Inventories | 151 | 119 | 87.44 | 140 | 127 | 76.35 | 44.04 |
| Sundry debtors | 374 | 355 | 256 | 284 | 243 | 206 | 270 |
| Cash & bank balances | 111 | 464 | 159 | 86.34 | 130 | 76.41 | 98.25 |
| Loans & advances | 728 | 567 | 443 | 454 | 444 | 445 | 201 |
| Total current assets | 1,364 | 1,505 | 945 | 964 | 944 | 804 | 613 |
| Total current liabilities | 693 | 545 | 265 | 283 | 259 | 208 | 222 |
| Net working capital | 670 | 960 | 680 | 681 | 685 | 595 | 390 |
| Total assets | 2,804 | 2,504 | 1,924 | 1,841 | 1,841 | 1,548 | 1,145 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 91.05 | 11.97 | 35.53 | 116 | 40.62 | 41.40 | 192 |
| Net cash from operating activities | 509 | 314 | 263 | 219 | 105 | (36.38) | 116 |
| Net cash from investing activities | (395) | (536) | (191) | (99.00) | (102) | (260) | (262) |
| Net cash from financing activities | (124) | 301 | (95.30) | (201) | 71.92 | 296 | (4.07) |
| Net change in cash | (9.14) | 79.08 | (23.56) | (80.25) | 75.15 | (0.78) | (150) |
| Closing cash | 111 | 464 | 159 | 86.34 | 130 | 76.41 | 98.25 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +29.4% | +15.7% | +20.4% | +40.0% | +14.4% | +4.7% | - |
| EBITDA growth | +53.2% | +42.0% | +70.0% | +33.8% | -24.6% | -0.2% | - |
| PBT growth | +104.7% | +108.5% | +565.6% | +69.2% | -88.2% | -24.9% | -3.5% |
| Net income growth | +107.4% | +107.1% | +710.8% | +301.0% | -108.3% | -20.0% | - |
| Revenue CAGR (3Y) | +21.7% | +24.9% | +24.5% | +18.8% | +7.8% | - | - |
| EBITDA CAGR (3Y) | +54.7% | +47.9% | +19.7% | +0.2% | -10.4% | - | - |
| Profitability & leverage | |||||||
| Net income margin | +15.9% | +10.0% | +5.7% | +0.8% | +0.7% | +8.0% | +10.5% |
| Return on capital employed | +19.1% | +13.8% | +10.5% | +5.3% | +3.1% | +8.6% | +12.1% |
| Return on net worth | +15.1% | +11.0% | +8.9% | +1.1% | -0.6% | +7.4% | +10.1% |
| Debt / equity | 0.14 | 0.41 | 1.00 | 0.95 | 0.80 | 0.57 | 0.37 |
| Long-term debt / equity | 0.07 | 0.20 | 0.49 | 0.43 | 0.31 | 0.20 | 0.10 |
| Interest cover | 8.93 | 29.10 | 52.22 | 116.64 | 151.21 | 37.76 | 19.21 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.93 | 0.89 | 0.95 | 1.03 | 0.97 | 0.91 | 1.12 |
| Inventory turnover | 16.25 | 16.43 | 12.91 | 9.14 | 8.56 | 12.62 | 16.40 |
| Debtors turnover | 6.02 | 5.55 | 5.42 | 4.62 | 3.88 | 3.20 | 2.88 |
| EPS (βΉ) | 16.48 | 8.16 | 46.89 | 5.67 | 3.55 | 35.06 | 46.59 |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 38.33 | 39.63 | 0.00 | 0.00 |
| Book value per share (βΉ) | 117.28 | 102.12 | 551.96 | 503.80 | 500.21 | 494.88 | 484.03 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 647 | 547 | 594 | 549 | 527 | 483 | 567 | 429 |
| Revenue growth (YoY) | +22.9% | +13.2% | +4.8% | +28.1% | +37.9% | +82.6% | - | - |
| Other income | 3.84 | 3.54 | 16.04 | 8.45 | 14.93 | 10.01 | 9.82 | 9.45 |
| Total expenses | 469 | 407 | 426 | 378 | 387 | 370 | 413 | 317 |
| EBITDA | 178 | 140 | 168 | 171 | 140 | 113 | 154 | 111 |
| EBITDA margin | +27.5% | +25.6% | +28.3% | +31.1% | +26.6% | +23.4% | +27.1% | +25.9% |
| Depreciation | 44.40 | 42.13 | 41.16 | 40.60 | 36.21 | 34.33 | 34.10 | 31.07 |
| Interest | 9.33 | 5.98 | 6.16 | 8.06 | 7.70 | 10.70 | 9.16 | 21.66 |
| Profit before tax | 128 | 95.33 | 137 | 130 | 111 | 77.98 | 120 | 67.91 |
| Tax | 32.30 | 23.99 | 34.32 | 32.84 | 27.92 | 19.62 | 30.53 | 16.85 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 2,153 | 1,642 | 1,419 | 1,157 | 841 | 751 | 725 |
| Revenue growth | +31.1% | +15.7% | +22.6% | +37.6% | +11.9% | +3.6% | - |
| Other income | 49.13 | 37.34 | 29.33 | 27.96 | 28.15 | 27.29 | 17.84 |
| Total expenses | 1,560 | 1,250 | 1,131 | 991 | 716 | 587 | 556 |
| Employee cost | 618 | 486 | 431 | 354 | 263 | 204 | 202 |
| EBITDA | 593 | 392 | 288 | 167 | 125 | 164 | 170 |
| EBITDA margin | +27.6% | +23.9% | +20.3% | +14.4% | +14.9% | +21.9% | +23.4% |
| Depreciation | 152 | 126 | 107 | 87.77 | 79.70 | 71.77 | 52.36 |
| Interest | 34.08 | 71.94 | 81.15 | 74.38 | 50.98 | 32.11 | 21.26 |
| Profit before tax | 456 | 232 | 129 | 32.68 | 22.36 | 87.59 | 114 |
| Tax | 115 | 58.26 | 33.78 | 8.45 | 6.67 | 22.28 | 33.95 |
| Net profit | 348 | 175 | 95.22 | 24.61 | 4.38 | 65.31 | 80.13 |
| Net profit margin | +16.2% | +10.7% | +6.7% | +2.1% | +0.5% | +8.7% | +11.1% |
| EPS (βΉ) | 16.12 | 8.32 | 53.92 | 13.76 | 8.93 | 36.65 | 48.92 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 21.18 | 20.84 | 18.05 | 18.01 | 17.94 | 17.82 | 16.38 |
| Reserves & surplus | 2,487 | 2,147 | 993 | 895 | 873 | 850 | 777 |
| Shareholders' funds (net worth) | 2,508 | 2,167 | 1,011 | 913 | 891 | 868 | 794 |
| Secured loans | 95.13 | 129 | 710 | 699 | 718 | 603 | 291 |
| Unsecured loans | 128 | 159 | 157 | 170 | 33.80 | 33.98 | 12.42 |
| Total debt | 223 | 287 | 868 | 869 | 751 | 637 | 304 |
| Total liabilities | 2,763 | 2,478 | 1,899 | 1,802 | 1,790 | 1,545 | 1,137 |
| Assets | |||||||
| Gross block | 2,413 | 1,944 | 1,526 | 1,270 | 884 | 815 | 784 |
| Net block | 1,705 | 1,378 | 1,074 | 923 | 701 | 659 | 617 |
| Capital work in progress | 270 | 124 | 107 | 151 | 345 | 236 | 78.97 |
| Investments | 163 | 114 | 80.27 | 80.27 | 63.56 | 63.36 | 22.38 |
| Inventories | 150 | 118 | 86.07 | 138 | 126 | 73.33 | 42.93 |
| Sundry debtors | 370 | 353 | 259 | 277 | 237 | 203 | 269 |
| Cash & bank balances | 108 | 458 | 152 | 80.02 | 124 | 70.10 | 92.97 |
| Loans & advances | 725 | 565 | 454 | 457 | 457 | 446 | 204 |
| Total current assets | 1,352 | 1,495 | 951 | 952 | 944 | 792 | 609 |
| Total current liabilities | 711 | 548 | 254 | 268 | 253 | 208 | 208 |
| Net working capital | 641 | 947 | 697 | 684 | 690 | 584 | 401 |
| Total assets | 2,763 | 2,478 | 1,899 | 1,802 | 1,790 | 1,545 | 1,137 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 85.12 | 5.17 | 29.21 | 109 | 34.31 | 36.12 | 188 |
| Net cash from operating activities | 495 | 330 | 251 | 221 | 88.38 | (25.94) | 109 |
| Net cash from investing activities | (393) | (565) | (190) | (111) | (94.63) | (279) | (259) |
| Net cash from financing activities | (109) | 314 | (84.63) | (190) | 80.95 | 304 | (1.40) |
| Net change in cash | (6.52) | 79.95 | (24.04) | (79.80) | 74.70 | (1.81) | (152) |
| Closing cash | 108 | 458 | 152 | 80.02 | 124 | 70.10 | 92.97 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +31.1% | +15.7% | +22.6% | +37.6% | +11.9% | +3.6% | - |
| EBITDA growth | +51.3% | +36.2% | +72.6% | +33.6% | -23.9% | -3.3% | - |
| PBT growth | +96.9% | +79.6% | +294.8% | +46.2% | -74.5% | -23.2% | +1.6% |
| Net income growth | +99.2% | +83.6% | +286.9% | +461.9% | -93.3% | -18.5% | - |
| Revenue CAGR (3Y) | +23.0% | +25.0% | +23.6% | +16.9% | +6.6% | - | - |
| EBITDA CAGR (3Y) | +52.6% | +46.5% | +20.6% | -0.6% | -10.6% | - | - |
| Profitability & leverage | |||||||
| Net income margin | +15.9% | +10.6% | +6.7% | +2.1% | +1.9% | +8.7% | +11.1% |
| Return on capital employed | +18.7% | +13.9% | +11.4% | +6.0% | +3.7% | +8.9% | +12.6% |
| Return on net worth | +14.6% | +10.9% | +9.9% | +2.7% | +0.5% | +7.9% | +10.6% |
| Debt / equity | 0.11 | 0.36 | 0.90 | 0.90 | 0.79 | 0.57 | 0.37 |
| Long-term debt / equity | 0.04 | 0.16 | 0.41 | 0.39 | 0.31 | 0.18 | 0.09 |
| Interest cover | 7.73 | 27.01 | 44.88 | 94.03 | 112.81 | 34.75 | 18.09 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.99 | 0.95 | 1.02 | 1.08 | 0.99 | 0.94 | 1.14 |
| Inventory turnover | 16.06 | 16.07 | 12.66 | 8.77 | 8.44 | 12.93 | 16.61 |
| Debtors turnover | 5.96 | 5.37 | 5.29 | 4.50 | 3.83 | 3.18 | 2.88 |
| EPS (βΉ) | 16.12 | 8.32 | 53.92 | 13.76 | 8.93 | 36.65 | 48.92 |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 38.33 | 39.63 | 0.00 | 0.00 |
| Book value per share (βΉ) | 118.42 | 104.00 | 572.28 | 517.79 | 507.50 | 486.92 | 484.05 |
Timeline of Sai Life Sciences
5 dated milestones of Sai Life Sciences across 25 years, from founding to its latest funding, stage changes and deals.
- Founded Sai Life Sciences is founded.
- Funding First funding round of $1.6M.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Angel Round, of $1.1M.
- IPO Lists on the stock exchange (IPO).
Web traffic of Sai Life Sciences
The website of Sai Life Sciences (sailife.com) receives about 38.9K visits a month and ranks #915,798 among all websites worldwide, #1,098 in Biotechnology and Pharmaceuticals.
- Monthly visits38.9K
▲ 24.1% vs previous month
- Unique visitors13.3K
per month
- Global rank#915,798
among all websites
- Category rank#1,098
Health · Biotechnology and Pharmaceuticals
- Bounce rate31%
- Pages per visit2.3
- Average visit1 min 21 sec
- DevicesDesktop 22% Β· Mobile 78%
Websites whose visitors overlap most with Sai Life Sciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cuebiopharma.com | 100% | 4.9K | #7,063,180 | View details | |
| sherlock.bio | 100% | 2.8K | #4,929,420 | View details | |
| ornatx.com | 97% | 4.4K | #3,250,511 | View details | |
| dynotx.com | 96% | 14.4K | #2,089,404 | View details | |
| bioagilytix.com | 94% | 41.6K | #919,146 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 12 similar websites and full traffic analytics for Sai Life Sciences
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Sai Life Sciences (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 2,062 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 548 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sai Life Sciences
Complete news archive for Sai Life Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sai Life Sciences
Sai Life Sciences was founded in 1999 and raised its 1st funding round 7 years after it was founded.
Sai Life Sciences is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Krishna Kanumuri is the CEO of Sai Life Sciences, as recorded in our data.
Sai Life Sciences is a funded company, having raised a total of $112.18M across 10 funding rounds to date. The company's 1st funding round was a Series A of $1.57M, raised on Aug 2006.
Sai Life Sciences has 3,077 employees.
The primary company behind Sai Life Sciences, Sai Life Sciences Limited, reported revenue of βΉ2,242 Cr for FY 2026, up 29% year on year.
Sai Life Sciences was founded in 1999 in Hyderabad, India, and operates in the pharmaceutical sector. Services in drug discovery, development, and manufacturing of complex small molecules are offered, including synthetic and medicinal chemistry, pre-clinical toxicology, and DMPK studies. CMC operations cover pre-formulation, analytical development, stability studies, lyophilization, liposome processes, and formulation development.
Yes, Sai Life Sciences is publicly traded on NSE under the ticker symbol SAILIFE.
Sai Life Sciences has 15 investors. Key investors include Tata Capital, TPG, HBM Healthcare Investments, Fred Cohen, and Jagdish V Dore.
The valuation of Sai Life Sciences is $563.73M as of Jul 2024.
Sai Life Sciences is associated with 3 legal entities: Sai Life Sciences Limited, Sai Life Drugform Private Limited, Sai Life Pharma Private Limited.
The legal entities of Sai Life Sciences currently have 9 directors, including Krishnamraju Kanumuri, Ranga Raju Kanumuri, Runa Karan and others.
